VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce the Company has closed the first tranche, representing the majority of its previously announced upsized non-brokered private placement (the “Upsized Offering”), raising gross proceeds of $25,134,145 through the issuance of 6,981,707 units…
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Navan, Inc. (NASDAQ: NAVN) common stock pursuant and/or traceable to Navan’s offering documents issued in connection with Navan’s October 31, 2025 initial public offering (the “IPO”), have until Friday, April 24, 2026 to seek appointment…
SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- Makko AI, Inc., today announced that its AI-powered 2D game studio is live at makko.ai, following a beta period focused on product quality and creator feedback. Makko helps anyone turn a game idea into cohesive 2D art assets and playable prototypes without traditional drawing, animation, or coding workflows.
VANCOUVER, British Columbia, April 19, 2026 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announced today an update on the near-term operational plan related to the fire that occurred in certain areas of the crushing circuit at the Goose Mine in the evening of April 16, 2026,…
SINGAPORE, April 19, 2026 (GLOBE NEWSWIRE) -- SQRIL, the leading cross-border QR code payment infrastructure for emerging markets, today announced its official expansion into Africa. Starting today, SQRIL’s API enables users to perform seamless stablecoin-to-fiat QR code transactions across Tanzania, Kenya, and South Africa, marking a major leap in financial interoperability for the continent.
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal…
